Johnson & Johnson $JNJ stock has formed a classic candle over candle reversal with an oversold RSI as of March 5, 2023. This is a classic buy indicator for swing and position traders.
Bristol-Myers and Johnson & Johnson launch Phase 3 trial of milvexian
The Phase 3 Librexia study of milvexian, an investigational oral factor XIa-FXIa-inhibitor, will begin on March 2, 2023, according to a joint announcement from Bristol Myers Squibb and Johnson & Johnson. In three indication-seeking studies, the Librexia program—the largest FXIa development program to date—will collect data from close to 50,000 patients. The Librexia STROKE trial, which is evaluating milvexian in addition to standard antiplatelet therapy for stroke prevention in patients after an acute ischemic stroke or high-risk transient ischemic attack, has started accepting participants. Both the Librexia ACS and Librexia AF trials, which will compare milvexian to apixaban for the prevention of stroke in patients with atrial fibrillation, will begin in the first half of 2023. The Librexia ACS trial will assess event reduction in acute coronary syndromes in addition to standard of care antiplatelet therapy. Milvexian’s phase 2 proof-of-concept data showed that it had a distinct antithrombotic profile when used both alone and in conjunction with antiplatelet therapy. Within the first half of 2023, enrollment in the Librexia ACS and Librexia AF trials is anticipated to begin.
Johnson & Johnson’s Stelara demonstrates long-term efficacy in Crohn’s disease
IL-12 and IL-23 antagonist Stelara (ustekinumab), made by Johnson and Johnson, showed long-term durable efficacy and safety in the treatment of Crohn’s disease, according to new data. According to four-year results from a long-term extension study evaluating the effectiveness of Stelara, at week 200, 80% of patients taking the biologic demonstrated a clinical response, while 58% were in clinical remission. Additionally, endoscopic improvement was seen in 67% of patients receiving active treatment. According to a long-term pooled safety analysis, Stelara has a good safety profile over four years with only minor adverse events.
Johnson & Johnson initiated with Neutral at Guggenheim
Johnson and Johnson was given coverage by Guggenheim on March 1, 2023, with a Neutral rating and a $161 price target. Guggenheim supports the company’s decision to move forward with the Consumer Health separation and thinks the MedTech sector is exhibiting reasonable signs of recovery. Given an impending series of patent expirations, including Stelara later this year, Guggenheim would like more transparency on the Pharma industry’s outlook. The company’s forecast falls short of management’s projections for $60 billion in pharmaceutical salesThe income statement provides a summary of a company's revenue and expenses over a specified period of time, typically a year or a quarter. It shows the company's total revenue, th... in 2025 and several pipeline assets with $1 billion or $5 billion in peak annual sales potential that they have highlighted.
